Previous 10 | Next 10 |
Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company’s IND Application IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second Quarter of this Year, Respectively Kiromic BioPharma,...
ISS and Glass Lewis Join the Kiromic Board of Directors in Recommending Stockholders Vote “ FOR ” for All Three Proposals at the Special Meeting of Kiromic Stockholders to be Held on March 7, 2023 Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the...
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-o...
Kiromic BioPharma ( NASDAQ: KRBP ) appoints Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of R&D and Clinical Translation since September 2021 and his previous ro...
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies wit...
Penny stocks are beginning to heat up again. While the broader stock market indexes waiver in the wake of the latest Federal Reserve meeting minutes, traders are charging ahead & buying into volatile stocks. One of the biggest reasons behind the shift from investing and into trading is ...
Construction Completion is One of the Pre-requisites to Beginning the Deltacel™ Clinical Trial Activation Later This Year and Addresses a Key Clinical Hold Citation Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) , ...
IND for Non-Engineered Deltacel/KB-GDT ™ to be Submitted in the Second Half of 2022 with Beginning of Clinical Trial Activation Expected by Year-End Three Additional IND Filings Will Expand the Company’s Pipeline to Five Allogeneic Gamma Delta T-cell Clin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiromic BioPharma ( KRBP ) stock is taking off on SRA news. This has it planning to submit three new NDAs. These will focus on GDT allogeneic therapies. Source: Shutterstock Kiromic BioPharma (NASDAQ: ...
NEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Kiromic BioPharma (NASDAQ: KRBP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: V...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...